Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen

Gut

Volumn 53, Issue 12, 2004, Pages 1850-1855

  Dielricli, C G ^a   Geier, A ^a   Wasmuth, H E ^a   De Waart, D R ^b   Elferink, R P J Oude ^b   Matern, S ^a   Gartung, C ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; BREAST CANCER RESISTANCE PROTEIN 2; CARBON 14; CARCINOGEN; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BILE FLOW; BILIARY CIRRHOSIS; BINDING AFFINITY; BREAST CANCER; CANCER INCIDENCE; CANCER RESISTANCE; CHEMICAL CARCINOGENESIS; CHOLESTASIS; COLON; CONTROLLED STUDY; DATA ANALYSIS; DETOXIFICATION; DRUG DETOXIFICATION; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; FOOD CONTAMINATION; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY PARENCHYMA; LIVER; LIVER CANCER; LIVER CIRRHOSIS; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIOACTIVITY; RAT; TISSUE DISTRIBUTION; XENOBIOTIC METABOLISM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; CARCINOGENS; FEMALE; FOOD CONTAMINATION; GLUCURONOSYLTRANSFERASE; IMIDAZOLES; LIVER; LIVER CIRRHOSIS, BILIARY; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, DRUG; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 9344242439     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.037507     Document Type: Article

References (38)

1. Kuper H, Ye W, Broome U, et al. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001;34:714-18.
2. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998;28:921-5.
3. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7.
4. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404-8.
5. Lee J, Boyer JL. Molecular alterations in hepatocyte transpart mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 2000;20:373-84.
6. Bastien MC, Leblond F, Pichette V, et al. Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis. Can J Physiol Pharmacol 2000;78:9112-9.
7. Debinski HS, Mackenzie PI, Lee CS, et al. UDP glucuronosyltransferase in the cirrhotic rat liver. J Gastroenterol Hepatol 1996;11:373-9.
8. Paulusma CC, Kothe MJ, Bakker CT, et al. Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver. Hepatology 2000;31:684-93.
9. Dietrich CG, Ottenhoff R, de Waart DR, et al. Lack of UGT1 isoforms in Gunn rats changes metabolic ratio and facilitates excretion of the food-derived carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine. Toxicol Appl Pnarmacol 2001;170:137-43.
10. Eisenbrand G, Tang W. Food-borne heterocyclic amines. Chemistry, formation, occurrence and biological activities. A literature review. Toxicology 1993;84:1-82.
11. Crofts FG, Sutter TR, Strickland PT. Metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis 1998;19:1969-73.
12. Dietrich CG, de Waart DR, Ottenhoff R, et al. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2- amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP). Carcinogenesis 2001;22:805-11.
13. Dietrich CG, de Waart DR, Ottenhoff R, et al. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol Pharmacol 2001;59:974-80.
14. van Herwaarden AE, Jonker JW, Wagenaar E, et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res 2003;63:6447-52.
15. Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003;52:1788-95.
16. Nowell SA, Massengill JS, Williams S, et al. Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4, 5- b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. Carcinogenesis 1999;20:1107-14.
17. Long MP, Nowell S, Malfatti MA, et al. In vivo human metabolism of [2-14C]2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine (PhIP). Cancer Lett 1999;143:135-8.
18. Langouet S, Paehler A, Welti DH, et al. Differential metabolism of 2-amino-1methyl-methyl-6-pnenylimidazo[4,5-b]pyridine in rat and human hepatocytes. Carcinogenesis 2002;23:115-22.
19. Ito N, Hasegawa R, Sano M, et al. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis 1991;12:1503-6.
20. Berlau J, Glei M, Pool-Zobel BL. Colon cancer risk factors from nutrition. Anal Bioanal Chem 2004;378:737-43.
21. Sinha R. An epidemiologic approach to studying heterocyclic amines. Mutat Res 2002;506-507:197-204.
22. Dietrich CG, Geier A, Salein N, et al. Consequences of bile-duct obstruction on intestinal expression and function of Multidrug resistance-associated protein 2. Gastroenterology 2004;126:1044-53.
23. Watkins BE, Esumi H, Wakabayoshi K, et al. Fate and distribution of 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine (PhIP) in rats. Carcinogenesis 1991;12:1073-8.
24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
26. van Es HH, Goldhoorn BG, Paul-Abrahamse M, et al, Immunochemical analysis of uridine diphosphate-glucuronosyltransferase in four patients with the Crigler-Najjar syndrome type I. J Clin Invest 1990;85:1199-205.
27. Geier A, Dietrich CG, Voigt S, et al. Effects of proinflammatory cytokines on rat orqanic anion transporters during toxic liver injury and cholestasis. Hepatology 2003;38:345-54.
28. Morrow CS, Smitherman PK, Townsend AJ. Role of multidrug-resistance protein 2 in glutathione S-transferase P1- 1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol Carcinog 2000;29:170-8.
29. Kaderlik KR, Minchin RF, Mulder GJ, et al. Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues. Carcinogenesis 1994;15:1703-9.
30. Malfatti MA, Connors MS, Mauthe RJ, et al. The capability of rat colon tissue slices to metabolize the cooked-food carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine. Cancer Res 1996;56:2550-5.
31. de Waziers I, Cugnenc PH, Yang CS, et al. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990;253:387-94.
32. Koepke JP, Jones S, DiBona GF. Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats. Am J Physiol 1987;252:R1019-23.
33. Oswald M, Kullak-Ublick GA, Paumgartner G, et al. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 2001;21:247-53.
34. Kullak-Ublick GA, Baretton GB, Oswald M, et al. Expression of the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. Hepatol Res 2002;23:78-82.
35. Turesky RJ, Constable A, Fay LB, et al. Interspecies differences in metabolism of heterocyclic aromatic amines by rat and human P450 1A2. Cancer Lett 1999;143:109-12.
36. Garner RC, Lightfoot TJ, Cupid BC, et al. Comparative biotransformation studies of MelQx and PhIP in animal models and humans. Cancer Lett 1999;143:161-5.
37. Lin DX, Lang NP, Kadlubar FF. Species differences in the biotransformation of the food-borne carcinogen 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine by hepatic microsomes and cytosols from humans, rats, and mice. Drug Metab Dispas 1995;23:518-24.
38. Magagnotti C, Pastorelli R, Pozzi S, et al. Genetic polymorphisms and modulation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-DNA adducts in human lymphocytes. Int J Cancer 2003;107:878-84.